标题
Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis
作者
关键词
-
出版物
JOURNAL OF IMMUNOLOGY
Volume 201, Issue 6, Pages 1605-1613
出版商
The American Association of Immunologists
发表日期
2018-09-05
DOI
10.4049/jimmunol.1800013
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristics
- (2018) E. Stoffel et al. BRITISH JOURNAL OF DERMATOLOGY
- Scanning the Immunopathogenesis of Psoriasis
- (2018) Andrea Chiricozzi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Research Techniques Made Simple: Murine Models of Human Psoriasis
- (2018) Jason E. Hawkes et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials
- (2018) Mark G. Lebwohl et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)
- (2018) Mark Lebwohl et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)
- (2018) Alice B. Gottlieb et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis
- (2018) Curdin Conrad et al. Nature Communications
- Sexy again: the renaissance of neutrophils in psoriasis
- (2017) Michael P. Schön et al. EXPERIMENTAL DERMATOLOGY
- Psoriasis pathogenesis and the development of novel targeted immune therapies
- (2017) Jason E. Hawkes et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Neutrophils are not the dominant interleukin-17 producer in psoriasis
- (2017) Keiichi Yamanaka et al. JOURNAL OF DERMATOLOGY
- The Snowballing Literature on Imiquimod-Induced Skin Inflammation in Mice: A Critical Appraisal
- (2017) Jason E. Hawkes et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis and comorbid diseases
- (2017) Junko Takeshita et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Psoriasis and comorbid diseases
- (2017) Junko Takeshita et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
- (2017) Peter Nash et al. LANCET
- Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
- (2017) Kristian Reich et al. LANCET
- Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
- (2017) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease
- (2016) Stephan R Targan et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
- (2016) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- A revolutionary therapeutic approach for psoriasis: bispecific biological agents
- (2016) T. Torres et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a
- (2016) Ka Lun Cheung et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL-12 protects from psoriasiform skin inflammation
- (2016) Paulina Kulig et al. Nature Communications
- IL-26: An Emerging Proinflammatory Member of the IL-10 Cytokine Family with Multifaceted Actions in Antiviral, Antimicrobial, and Autoimmune Responses
- (2016) Emmanuel Stephen-Victor et al. PLoS Pathogens
- Humanized anti–IFN-γ (HuZAF) in the treatment of psoriasis
- (2015) Jamie L. Harden et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Melanocyte antigen triggers autoimmunity in human psoriasis
- (2015) Akiko Arakawa et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
- (2015) Christopher E M Griffiths et al. LANCET
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Iain B McInnes et al. LANCET
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
- (2015) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
- (2014) Christopher Ritchlin et al. ANNALS OF THE RHEUMATIC DISEASES
- Identification of Cellular Pathways of "Type 1," Th17 T Cells, and TNF- and Inducible Nitric Oxide Synthase-Producing Dendritic Cells in Autoimmune Inflammation through Pharmacogenomic Study of Cyclosporine A in Psoriasis
- (2014) A. S. Haider et al. JOURNAL OF IMMUNOLOGY
- Composition of Innate Lymphoid Cell Subsets in the Human Skin: Enrichment of NCR + ILC3 in Lesional Skin and Blood of Psoriasis Patients
- (2014) Marcel B.M. Teunissen et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis prevalence among adults in the United States
- (2014) Tara D. Rachakonda et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis
- (2014) Roberto Lande et al. Nature Communications
- IL-17 and TNF Synergistically Modulate Cytokine Expression while Suppressing Melanogenesis: Potential Relevance to Psoriasis
- (2013) Claire Q.F. Wang et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Characterization of Innate Lymphoid Cells in Human Skin and Blood Demonstrates Increase of NKp44+ ILC3 in Psoriasis
- (2013) Federica Villanova et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
- (2013) Iain B McInnes et al. LANCET
- IL-29 Is Produced by TH17 Cells and Mediates the Cutaneous Antiviral Competence in Psoriasis
- (2013) K. Wolk et al. Science Translational Medicine
- Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential
- (2013) Alice Gottlieb et al. Therapeutic Advances in Musculoskeletal Disease
- Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
- (2012) Wolfgang Hueber et al. GUT
- Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
- (2011) A. M. Lin et al. JOURNAL OF IMMUNOLOGY
- Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
- (2011) A. Puel et al. SCIENCE
- Cutting Edge: A Critical Functional Role for IL-23 in Psoriasis
- (2010) G. Tonel et al. JOURNAL OF IMMUNOLOGY
- Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis
- (2010) Andrea Chiricozzi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
- (2010) Christopher E.M. Griffiths et al. NEW ENGLAND JOURNAL OF MEDICINE
- Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis
- (2009) Erin G. Harper et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells
- (2008) Michelle A. Lowes et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- (2008) Kim A Papp et al. LANCET
- A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity
- (2008) Marina Cella et al. NATURE
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
- (2007) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started